Article Abstract

ASCEND-5: too little too late?

Authors: Fengying Wu, Sai-Hong Ignatius Ou


Since the discovery of anaplastic lymphoma kinase (ALK)-rearrangement in non-small lung cancer (NSCLC) in 2007, there are now four approved ALK tyrosine kinase inhibitors (TKIs) (crizotinib, ceritinib, alectinib, brigatinib) in the US with the most recent one (brigatinib) approved in the US on April 28, 2017 (1).